Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients

被引:1
作者
Boutros, Andrea [1 ,2 ]
Vera, Lara [3 ]
Gatto, Federico [3 ]
Fornarini, Giuseppe [4 ]
Zanardi, Elisa [5 ]
机构
[1] IRCCS Osped Policlin San Martino, UO Oncol Med 2, Genoa, Italy
[2] Univ Genoa, Sch Med, Dept Internal Med & Med Special, Genoa, Italy
[3] IRCCS Policlin San Martino, Dept Internal Med, Endocrinol Unit, Genoa, Italy
[4] IRCCS Policlin San Martino, UO Oncol Med 1, Genoa, Italy
[5] IRCCS Osped Policlin San Martino, Dept Med Oncol, UO Clin Oncol Med, Genoa, Italy
关键词
pembrolizumab; axitinib; kidney cancer; hypothyroidism; myopathy; hypothyroid myopathy; immunotherapy; immune-relate adverse event; SUNITINIB;
D O I
10.3389/fonc.2022.1048526
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments, the determination of which drug is related to an adverse event may be challenging. We reported two cases of patients who developed muscle enzyme elevation in association with hypothyroidism during therapy with pembrolizumab plus axitinib for metastatic kidney cancer. The myopathy rapidly resolved after hormone replacement therapy with levothyroxine. Hypothyroid myopathy is a scarcely known and underreported adverse event. This adverse event may be relevant in the differential diagnosis with immune-related myositis, which has an autoimmune pathogenesis and a potentially fatal course.
引用
收藏
页数:5
相关论文
共 11 条
[1]   Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Powles, T. ;
Burotto, M. ;
Escudier, B. ;
Bourlon, M. T. ;
Zurawski, B. ;
Juarez, V. M. Oyervides ;
Hsieh, J. J. ;
Basso, U. ;
Shah, A. Y. ;
Suarez, C. ;
Hamzaj, A. ;
Goh, J. C. ;
Barrios, C. ;
Richardet, M. ;
Porta, C. ;
Kowalyszyn, R. ;
Feregrino, J. P. ;
Zolnierek, J. ;
Pook, D. ;
Kessler, E. R. ;
Tomita, Y. ;
Mizuno, R. ;
Bedke, J. ;
Zhang, J. ;
Maurer, M. A. ;
Simsek, B. ;
Ejzykowicz, F. ;
Schwab, G. M. ;
Apolo, A. B. ;
Motzer, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841
[2]  
Fariduddin MM., 2022, HYPOTHYROID MYOPATHY
[3]   Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen [J].
Figueroa-Perez, Nikole ;
Kashyap, Rahul ;
Bal, Deepinder ;
Khan, Syed Anjum ;
Pattan, Vishwanath .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
[4]   Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy [J].
He, Jian ;
Xu, Jiang ;
Gao, Jin ;
Qian, Liting .
EUROPEAN JOURNAL OF CANCER, 2021, 155 :38-41
[5]   Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma [J].
Motzer, Robert ;
Alekseev, Boris ;
Rha, Sun-Young ;
Porta, Camillo ;
Eto, Masatoshi ;
Powles, Thomas ;
Gruenwald, Viktor ;
Hutson, Thomas E. ;
Kopyltsov, Evgeny ;
Mendez-Vidal, Maria J. ;
Kozlov, Vadim ;
Alyasova, Anna ;
Hong, Sung-Hoo ;
Kapoor, Anil ;
Alonso Gordoa, Teresa ;
Merchan, Jaime R. ;
Winquist, Eric ;
Maroto, Pablo ;
Goh, Jeffrey C. ;
Kim, Miso ;
Gurney, Howard ;
Patel, Vijay ;
Peer, Avivit ;
Procopio, Giuseppe ;
Takagi, Toshio ;
Melichar, Bohuslav ;
Rolland, Frederic ;
De Giorgi, Ugo ;
Wong, Shirley ;
Bedke, Jens ;
Schmidinger, Manuela ;
Dutcus, Corina E. ;
Smith, Alan D. ;
Dutta, Lea ;
Mody, Kalgi ;
Perini, Rodolfo F. ;
Xing, Dongyuan ;
Choueiri, Toni K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) :1289-1300
[6]   Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].
Motzer, Robert J. ;
Penkov, Konstantin ;
Haanen, John ;
Rini, Brian ;
Albiges, Laurence ;
Campbell, Matthew T. ;
Venugopal, Balaji ;
Kollmannsberger, Christian ;
Negrier, Sylvie ;
Uemura, Motohide ;
Lee, Jae L. ;
Vasiliev, Aleksandr ;
Miller, Wilson H., Jr. ;
Gurney, Howard ;
Schmidinger, Manuela ;
Larkin, James ;
Atkins, Michael B. ;
Bedke, Jens ;
Alekseev, Boris ;
Wang, Jing ;
Mariani, Mariangela ;
Robbins, Paul B. ;
Chudnovsky, Aleksander ;
Fowst, Camilla ;
Hariharan, Subramanian ;
Huang, Bo ;
di Pietro, Alessandra ;
Choueiri, Toni K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1103-1115
[7]   Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [J].
Powles, Thomas ;
Plimack, Elizabeth R. ;
Soulieres, Denis ;
Waddell, Tom ;
Stus, Viktor ;
Gafanov, Rustem ;
Nosov, Dmitry ;
Pouliot, Frederic ;
Melichar, Bohuslav ;
Vynnychenko, Ihor ;
Azevedo, Sergio J. ;
Borchiellini, Delphine ;
McDermott, Raymond S. ;
Bedke, Jens ;
Tamada, Satoshi ;
Yin, Lina ;
Chen, Mei ;
Molife, L. Rhoda ;
Atkins, Michael B. ;
Rini, Brian, I .
LANCET ONCOLOGY, 2020, 21 (12) :1563-1573
[8]   Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline [J].
Rathmell, W. Kimryn ;
Rumble, R. Bryan ;
Van Veldhuizen, Peter J. ;
Al-Ahmadie, Hikmat ;
Emamekhoo, Hamid ;
Hauke, Ralph J. ;
Louie, Alexander, V ;
Milowsky, Matthew, I ;
Molina, Ana M. ;
Rose, Tracy L. ;
Siva, Shankar ;
Zaorsky, Nicholas G. ;
Zhang, Tian ;
Qamar, Rubina ;
Kungel, Terry M. ;
Lewis, Bryan ;
Singer, Eric A. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) :2957-+
[9]  
RIGGS JE, 1990, MIL MED, V155, P171
[10]   Immune Checkpoint Inhibitor-Associated Myositis A Distinct Form of Inflammatory Myopathy [J].
Saygin, Didem ;
Ghosh, Nilasha ;
Reid, Pankti .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (07) :367-373